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INTRODUCTION 
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INTRODUCTION 
 
 
 
In recent years, there has been increasing evidence which shows 
strong links between inflammation and the pathogenesis of 
atherothrombotic stroke. Acute phase proteins have been implicated to 
play roles both during acute and chronic inflammatory processes in 
different diseases including ischemic stroke. Even low grade infections 
may cause elevation of various acute phase reactants which may partly 
be responsible for the inflammatory process observed in atherosclerotic 
lesions, which may inturn relate to occurrence of ischemic symptoms. 
 
Inflammation plays a major role in atherothrombosis and 
measurement of inflammatory markers such as C–Reactive Protein, an 
acute phase reactant that reflects low-grade systemic inflammation has 
been studied in a variety of cardiovascular diseases. There is growing 
evidence of the prognostic importance of CRP in ischemic stroke. Also 
CRP has been found to be a strong but relatively non-specific risk factor 
of fatal stroke in elderly persons. 
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CRP, a sensitive meter of inflammation, induces vascular thrombosis by 
stimulating monocytes to express tissue factor, the initiator of the 
extrinsic pathway of coagulation. Elevated levels of CRP are found to be 
related with higher risk of first-ever cardiovascular, cerebrovascular and 
peripheral vascular diseases. 
 
 
The WHO has recently set international reference standard for the 
use of highly sensitive CRP assays. This has enhanced the usefulness of 
CRP as a reliable predictor of cardiovascular events. 
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AIMS AND 
OBJECTIVES 
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AIM 
 
 
 
1. To evaluate the predictive value of hs-CRP in relation to first ever 
ischemic stroke. 
 
2. To correlate the hs-CRP levels with various cardiovascular risk 
factors. 
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REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
 
CEREBROVASCULAR ACCIDENT / STROKE: 
 
       Cerebrovascular accident or stroke occurs due to sudden 
death of brain cells in a localised area of the brain due to 
inadequate or lack of blood flow. 
          Depending on the area affected it can cause loss of memory, 
loss of speech, inability to move limbs, coma or even death. 
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CAUSES OF CEREBRAL ISCHEMIA AND INFARCTION 
• Congenital arterial anomalies 
• Dissection 
• Atherthromboembolism 
• Intracranial small vessel disease (lipohyalinosis, 
microatheroma) 
• Arterial Wall disorder 
• Trauma 
• Inflammatory vascular disease 
• Embolism from the heart 
•  Irradiation, infection      
• Moya Moya syndrome 
• Binswanger disease 
• Embolism from arterial aneurysm 
• Hematological disorders 
• Fibromuscular dysplasia 
• Paradoxical emboli 
• Miscellaneous: 
Migraine 
Pregnancy 
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Cancer 
                    Drug Abuse 
OCP 
Homocystinemia 
IBD 
Fabry’s disease 
Mitochondrial Cytopathy 
Hypoglycemia 
Hypercalcemia 
Fat embolism 
Epidermal nevus syndrome 
Acute leukemia’s 
SLE 
Anti thrombin III deficiency 
Protein C Defeciency 
Protein S deficiency 
Factor V leiden Mutation 
Hypercoagulable states 
 
Thus it is evident that: 
 50% cases of CVA is due to athero embolism of cerebral artery 
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 80% CVA is due to cerebral infarction 
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STROKE IN YOUNG 
Occurs in < 40 yrs of age  
Causes:  
I. Infants and children – 
 CAHD 
 AVM 
 Thrombosis of veins 
II. Children and Young adults- 
1. CVS – 
 RHD 
 IE 
 Embolism 
 Prosthetic valve  
 MVP 
 Left atrial myxoma 
2. Arteritis –  
 TB 
 Syphilis 
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 Takayasu’s arteritis  
 aortoarteritis 
3. Collage vascular disease- 
 SLE 
 APLAS  
 Rheumatoid arthritis 
 Mayo-mayo’s disease 
4. Inborn errors of metabolism 
 Homocystinuria 
 Allopunuria  
5. Haematological causes 
 Sickle cell disease 
 G6PD deficiency 
6. Congenital causes- 
 factor 12 deficiency 
 high concentration of factor 8 
 hyperfibrinogenaemia 
 heparin co factor II defeciency 
 hyperhomocyteinemia 
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ATHEROSCLEROSIS 
 
        Atherosclerosis remains the major cause of death and premature 
disability in the developed society. It affects various regions of 
circulation preferentially, and presents with distinct clinical picture, i.e, 
MI due to atherosclerosis of coronary blood vessel, atherosclerosis of 
blood vessels supplying the brain cause TIA & Stroke, in peripheral 
circulation it causes intermittent claudication, gangrene, it can also 
produce renal artery stenosis.  
There is accumulation of lipoproteins within the initmal layers of blood 
vessel and then bind to matrix macromolecules and undergoes oxidative 
damage, furthermore leads on to production of inflammatory cells within 
the plaque. Inflammatory cells like monocyte derived macrophages and 
lymphocytes along with various cell adhesion molecules accumulate at 
the site of plaque. Macrophages evolve into foam cell rich in lipid then 
leading on to the formation of fatty streak (precursor of fully formed 
athermatous plaque) 
Adipose tissue derived macrophages may be the primary source of many 
proinflammatory cytokines, like - CRP, IL -1 , 6 , 8 ; resistin , TNF – 
alpha. 
CRP has been used to understand the inflammatory components of 
atherosclerosis than other inflammatory mediators such as IL-6 & TNF –
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alpha.  CRP has been researched over a decade in the role of 
atherosclerotic diseases. Its assessment can give an approach towards 
prognosis in ACS & CVA patients especially in first ever stroke. 
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RISK FACTORS FOR STROKE 
 
           Since stroke is a multifactorial disease, both environmental and  
and genetic risks affect the disease. 
1. Age and gender 
Stroke incidence increases with age. Risk doubles with each 
decade after 55 years. Approximately 80% of strokes occur in  elderly 
persons.Sex of the person also affects the risks. Men develop strokes at a 
higher rate than women up to age of 75. 
2. Smoking: 
     Smoking is a well established risk factor for stroke. A meta-analysis 
has shown a 50% increase in stroke risk among the  smokers. 
3. Diabetes Mellitus: 
           Diabetes increases stroke risk to 2 to four fold compared to non-
diabetes subjects and also increasing mortality and morbidity after 
stroke. 
4. Hypertension:  
         High blood pressure damages the entire arterial tree, it’s a 
modifiable risk factor in acute CVA / ACS .  
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5. Hypercholestrolemia: 
         Both elevated LDL as well as serum cholesterol increases the risk 
of stroke  and CHD. 
6. Homocysteinemia: 
             Hyperhomocysteinemia has been described as a possible risk 
factor for ischemic stroke. Presumed mechanism is raised stress 
tolerance of the endothelium, inflammation,thrombosis, and oxidative 
stress. 
7. Inflammation and bio-markers: 
           Inflammation as part of atherosclerotic pathway has been 
implicated in ischemic stroke and cardiovascular disease. Inflammatory 
 17 
biomarkers such as HSP, IL-6 and CRP have been shown to be increased 
in acute ischemic stroke. 
8. Evidence of existing vascular disease: 
 Myocardial infarction 
 Cardiac failure 
Peripheral vascular disease 
Atrial fibrillation 
 Carotid arterial bruit and stenosis 
Transient ischemic attacks 
9. Miscellaneous: 
Plasma fibrinogen, Alcohol, OCP 
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PREDICTORS OF STROKE OUTCOME 
I) Demographic factors: 
1. Age: 
Age is one of the major  risk factors that negatively influence the 
outcome of patients with ischemic stroke. Recovery of elderly patients is 
less likely when compared to younger patients. 
2. Gender: 
       Few studies have shown men are associated with poor outcome 
whereas few other studies have shown no difference in predisposition. 
The explanation for this might be hormonal. Oestrogen seems to be an 
important mediator of outcome after ischemic brain injury. 
3. Race/Ethnicity: 
          There is no significant difference in the outcome of incidence of 
stroke among different  races & ethinicity 
II) Cerebrovascular risk factors: 
1. Previous stroke and atrial fibrillation: 
        Patients with previous history of stroke and atrial fibrillation are 
associated with more severe, disabling and higher moratlity. 
III) Clinical findings: 
1. Level of consciousness and gaze deviation: 
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       Level of consciousness is an important predictor . The presence of 
gaze deviation & decreased level of consciousness predicts poor 
outcome. 
2. Blood Pressure: 
Abnormal blood pressure may influence outcome. High BP have 
negative long term effect on BBB function. And , so, decreased BP has 
shown decrease in blood flow in the infracted area. 
3. Temperature: 
        For each one degree celsius rise in body temperature, the relative 
risk of poor outcome increases twice . This is due to  increased 
concentration of excitotoxic neurotransmitters . Higher temperature 
(>37.50C) is an important predictor of large volume infarct and higher 
neurological deficit when it occurred in the first day after stroke onset. 
IV) Laboratory findings: 
1. Glycine and glutamate: 
      Raised glycine or glutamate levels strongly correlate with large 
infarct size and disabling neurological deficits. 
2. S-100: 
        Elevated  serum levels of S-100 correlate with poor neurologic 
outcome. 
3. Neuron-specific enolase: 
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         This enzyme has been shown to rise in acute stroke. 
4. Serum Glucose: 
         Elevated blood glucose is associated with increased mortality and 
morbidity. Elevated blood glucose seems to produce its negative effects 
by causing a profound cellular acidosis. Clinical studies have shown an 
correlation between elevated blood glucose and cerebral oedema. 
PROGNOSTIC VALUE OF ACUTE PHASE REACTANTS (APR) 
1. Erythrocyte Sedimentation rate (ESR): 
Raised  ESR predicts poor outcome. 
2. C-reactive protein (CRP): 
CRP concentrations measured within 3 days of stroke individually 
predicted survival after ischemic stroke. Patients with levels above 10.1 
mg/L had significantly poor survival rate. 
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C REACTIVE PROTEIN 
 
History and nomenclature: 
CRP founded in 1930 by William S Tillet and Thomas Francis is a 
petameric protein detected in the serum of patients with acute 
inflammation. 
 
Genetics and Biochemistry: 
 
The gene for CRP is located in 1q21-q23 , its an residue protein with 
molecular mass 25106Da. C stands for carbohydrate to which it bind to 
capsule of pneumococci. 
 
 
 
 22 
FUNCTION OF CRP 
      It’s a major component of acute phase proteins. It is generated in 
liver and is present in circulation in very low concentration ( <1mg/dl). 
It is involved in activation of immune system through complement 
cascade. 
 
 
DIAGNOSTIC USE 
      Estimation if CRP is important in evaluation on acute phase 
response, which useful to determine the disease process and success of 
the treatment. If the recovery is complicated by any infection it will be 
reflected by continuous elevation of its level which needs further 
intervention. 
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CRP IN ATHEROSCLEROSIS 
CRP has been used to understand the inflammatory components of 
atherosclerosis than other inflammatory mediators such as IL-6 & TNF –
alpha.  CRP has been researched over a decade in the role of 
atherosclerotic diseases. Its assessment can give an approach towards 
prognosis in ACS & CVA patients especially in first ever stroke. 
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DYNAMICS OF CRP 
            The acute phase response comprises the non-specific biochemical 
and physiological responses of endothermic animals to nearly every form 
of tissue damage, inflammation, neoplasia and infection.The synthesis of 
a number of protein is upregulated  in hepatocytes under the influence of 
a cascade of cytokines, including,  IL-6 ,IL-1 & TNF-α originating at the 
site of disease process. 
CRP levels rapidly increase after  inflammatory stimulus and 
depending upon the intensity of the stimulus, even a 100 fold increase in 
plasma levels may occur. CRP is not degraded to a significant extent in 
any process and its clearance is not influenced by any condition. Hence 
its concentration appears to be dependent on the rate of production and 
elimination. The t1/2 is 19  hours, which is long and makes it's detection 
in blood after several hours of stimulus. Because of this nature of CRP, it 
is called as an “ideal marker of inflammation”. 
 
CRP VS OTHER ACUTE PHASE PROTEINS 
Acute phase proteins includes, besides CRP, has other protein 
substances , such as albumin ,alpha 1 anti-trypsin , pro-calcitonin , 
ceruloplasmin , alpha 1 acid glycoprotein, fibrinogen, haptoglobin , alpha 
2 haptoglobin, and Serum Amyloid A. 
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The disadvantage of the above mentioned proteins is that the 
difference in normal and pathological values are negligible. The values 
seen in those conditions are  a few times than those found in healthy 
individuals. 
       Determination of SAA levels is difficult because of lack of methods 
to obtain routine measurements. CRP has an advantage that pathological 
values are easy to detect since the increase in concentration can be 
several hundred fold . 
 
Liver generated CRP is stimulated by chemokines secreted by 
macrophages& monocytes. The rise in level of IL-6 concentration in 
serum is  the earliest markers of inflammatory processes, detected within 
few hours after onset of infection.  IL-6 concentration is usually detected 
4 to 7 hours after the onset of infection,  depending on the sensitivity of 
the method used to detect. 
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HIGH SENSITIVITY CRP (hs-CRP) 
In 1990s, high sensitivity CRP assays started becoming available for 
measurement , allowing measurement of serum concentrations at the 
lower end . In the following years, hs-CRP levels were used , beneath the 
normal set value, indicating  immediate-phase response, predicting the 
risk of diabetes mellitus, cerebrovascular disease, cognitive impairement 
and cardiovascular disease. 
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Normal reference range: 0.02 to 8.0 mg/L 
 
 
ROLE OF ACUTE PHASE REACTANTS IN  
ACUTE ISCHEMIC STROKE 
       Adipose tissue derived macrophages may be the primary source of 
many proinflammatory cytokines, like - CRP, IL -1 , 6 , 8 ; resistin , TNF 
– alpha. These are responsible for atheroma formation , which is the 
preliminary process in thrombus formation and which leads on to 
CVA/ACS. 
 
 
Fibrinogen: 
It’s a soluble glycoprotein which constitutes 2-3% of plasma proteins, it 
consists of 4 polypeptide chains, it undergoes proteolytic cleavage to 
form thrombin, which is responsible for clot formation. Its used as 
marker in CVA to find out stroke severity and also in MI. It is a main 
component of plasma. It is involved in aggregation of platelets, 
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interactions between leucocytes and endothelial cells and primary 
hemostasis. 
Normal level in plasma = 200-400mg/dl 
Ferritin: 
        Ferritin is storage form of iron, it is stored in spleen, liver and bone 
marrow. It has a molecular weight of 4 lakhs, and can combine with 3000 
atoms of iron. The maximum iron content of ferritin on weight basis is 
around 25%. There are studies about the role of serum iron in ischemic 
stroke. Studies revealing poor prognosis associated with high iron level. 
Normal range: male – 12 to 300nanogram/ml,  
                       Female- 12-150nanogram/ml 
It has been well documented that increased serum ferritin level within 1 
day of admission in hospital following stroke is associated with poor 
prognosis. Even high levels of serum ferritin in CSF are said to have 
grave prognosis in CVA patients. 
 
CERULOPLASMIN:  
It’s a alpha 2 globulin synthesised in liver, contains 7 – 9 copper atoms 
per molecule. Responsible for iron incorporation into transferrin. 
Important anti-oxidant in plasma. It’s an acute phase reactant, its 
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increased in all inflammatory conditions, collage vascular disease, and 
malignancies. 
Normal Level in plasma – 25 to 50 mg/dl  
 
 
CRP: 
       Increased level of hs-CRP is associated with adverse cerebrovascular 
and cardiovascular events. Increased CRP associated with high mortality 
following stoke and occurrence of first episode of stroke and carotid 
stenosis. 
 
CRP AND ACS/CVA: 
             CRP has been used to understand the inflammatory components 
of atherosclerosis than other inflammatory mediators such as IL-6 & 
TNF –alpha.  CRP has been researched over a decade in the role of 
atherosclerotic diseases. Its assessment can give an approach towards 
prognosis in ACS & CVA patients especially in first ever stroke. 
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FRAMINGHAM STUDY: 
        The study described the relationship between hs-CRP level and 
stroke incidents. It has been found out that among male patients who had 
high levels of hs CRP levels had 5 times higher incidence of CVA. 
Among female patients who had highest CRP levels during the time of 
study, had 14 times high risk of CVA , after following up for a period of 
10 years. It has also been noted that those patients had 6 times more 
incidence of cardiaovascular and peripheral vascular events. Following 
the study , many studies were undertaken to prove this hypothesis.  
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RELATIONS OF hs-CRP TO VARIOUS VASCULAR EVENTS 
 
 
There is rising evidence supporting  that higher levels of hs-CRP is 
a predictor of cardiovascular disease  and  plays an vital role in the 
different stages of the development of atherosclerosis. 
 
 
In normal subjects even a moderate increase of hs-CRP within the 
normal range (hs-CRP <5 mg/L) is considered to be predictive for a 
 32 
variety of cardiovascular events, independent from other cardiovascular 
events 
             Many studies have shown significant relationship between high 
sensitive C-reactive protein with various cardiovascular risk factors like 
smoking,alcoholism,diabetes, hypertension,dyslipidemia and various 
other risk factors.        
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Correlations with other established risk factors including  body mass 
index ,homocysteine, total cholesterol, triglycerides, age, systolic and 
diastolic blood pressure,number of cigarettes smoked per day,D-dimers,  
fibrinogen, and; CRP levels are related inversely with exercise frequency 
and high density lipoprotein (HDL) . CRP has emerged as a strong, 
independent risk factor. 
 
A study was performed by So Yeon Ryu et al to evaluate the 
relation of hs-CRP with several cardiovascular risk factors such as white 
blood cell counts ,  smoking habit, blood pressure , blood glucose, serum 
lipids, body mass index,, routine exercise, alcohol drinking, age,in a 
cross-sectional survey. Plasma hs-CRP was measured by 
immunoturbidimetry in 202 subjects, aged over 50 years, who 
participated in health-check survey in a rural area of Jeollanamdo, Korea. 
Plasma hs-CRP level was 1.9 ± 3.0 mg/dL. He concluded that there were 
significant associations between hs-CRP levels and age, white blood cell 
counts, blood glucose, diastolic blood pressure, HDL-cholesterol, body 
mass index and smoking status. Though the correlation between plasma  
HDL-cholesterol and hs-CRP negatively significant, other blood lipid 
profile, such as total cholersetrol, LDL , TGL did not correlate 
sugnificantly. 
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With hs-CRP. Smoking is well supposed to give chemical and 
oxidative stress to cardiovascular system and cause inflammation. It has 
been reported that moderate alcohol consumption reduces circulating 
CRP. But in his study, the plasma hs-CRP level was not significantly 
affected by the alcohol drinking. 
 
Increased levels of hs-CRP and intima-media thickness of the 
common carotid arteries  are together shown to be associated with the 
occurrence of CVA. This was shown in a study conducted by Gulcin 
Benbir et al. He studied the relationship of increased hs-CRP levels with 
the extent of carotid atherosclerosis . He studied 104 patients aged 
between 30 to 92 yrs with acute ischemic stoke. The hs-CRP 
determination was performed  3 days after admission. The relationship 
between the hs-CRP level and the other risk factors were also evaluated 
in his study. All of the variables except HDL levels, failed to show a 
significant relationship with the hs-CRP levels. Only variable that 
showed a significant relation with the levels of the hs-CRP was HDL 
levels. It was shown that the major risk factors of the stroke were also 
associated with the higher levels of CRP and the treatment with 
antiplatelets and statins might have lowered the levels of CRP through 
their regulatory effects on the inflammation. High blood glucose,  High 
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blood pressure, HDL cholesterol, as well as triglycerides were found to 
be strongly associated with CRP in a study by Blackburn R. et al., 
(2001). 
 
In a study by Choi  et al., 2004, there was no significant 
association between carotid atherosclerosis and hs-CRP  in normotensive 
and hypertensive subjects. 
 
Smokers had higher WBC, fibrinogen, and CRP levels in a study 
by Magyar et al. (2004). Several CHD risk factors appear to modulate 
the inflammatory response and affect hs-CRP concentration. Smokers  
have been shown to have increased  concentration of several 
inflammatory markers, hs-CRP, including  IL-6, and ICAM-1. Increased 
ICAM -1 and IL -6 a were shown to be associated with increased risk of 
future first coronary events in both men and women who smoke. 
Smoking cessation reduces these markers. 
Diabetic patients are said to have increased hs-CRP levels,  In this 
regard, links between hs-CRP and the insulin resistance syndrome have 
also been reported . In addition, experimental findings suggest that 
increased blood pressure accelerates endothelial expression of 
infammatory cytokines and other inflammatory mediators. These 
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observations suggest that perhaps better control of diabetes and 
hypertension may attenuate the contribution of the inflammatory 
response to overall cardiovascular risk. Taken together, the available 
evidence thus supports the hypothesis that hs-CRP concentrations 
correlate with endothelial dysfunction . 
 
Also , another study by Liuzzo et al showed that in patients with 
severe unstable angina, hs-CRP concentrations >3 mg/L during hospi 
were associated with an increased incidence of recurrent angina, 
coronary revascularization, MI, and cardiovascular death. 
 
In a similar study of unstable angina, Ferreiros et al concluded that 
the prognostic value of hs-CRP in predicting adverse outcome at 90 days. 
 
A recent report by de Winter et al showed that hs-CRP 
concentrations >5 mg/L at admission in 150 patients with non-ST-
elevation acute coronary syndromes were associated with an increased 
incidence of major cardiac events within 6 months . 
 
Results from a population-based study in Russia The Arkhangelsk 
study conducted by M. Averina and his colleagues revealed U-shaped 
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association between hs-CRP and total alcohol intake. This U-shaped 
association became non-significant in both sexes after adjustment for 
age, BMI, smoking status, diabetes mellitus and cardiovascular 
medication. 
Another study conducted by Chrysohoou et al in 2003, showed a 
U-shaped relation of several biochemical parameters related to 
atherosclerosis including hs-CRP and the amount of alcoholic beverages 
consumed. 
   
     A study by Rasouli Mehdi et al in 2006 , showed that elevated hs-CRP 
was assosciated with male sex, diabetes, hypertension and high levels of 
serum glucose. 
 
Another study by Minna Soinio et al concluded that diabetic 
patients have higher levels of hs-CRP than people without diabetes and 
that elevated hs-CRP levels are an independent risk factor for death from 
CHD in people with diabetes 
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MATERIALS AND METHODS 
 
 
 
Setting: 
 
 
Medical ward , Govt. Kilpauk Medical College, Chennai. 
 
 
Study design: 
 
 
Prospective hospital based study. 
 
 
Period of study: 
 
 
Jan  2015 to June 2015 
 
 
Inclusion criteria: 
 
 
1. All patients who presented within 48 hours of onset of stroke and 
who gave informed consent to participate in the study were 
included. 
 
Exclusion criteria: 
 
1. Subarachnoid haemorrhage, subdural haemorrhage and 
intracerebral haemorrhage were excluded with the aid of CT scan. 
 
2. Patients above 70 years of age were excluded. 
 
3. Patients with evidence of active infection and neoplastic conditions 
at the time of study were excluded. 
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4. Patients with rheumatic heart disease and collagen vascular disease 
were excluded. 
 
5. Patients who were actively smoking at the time of study were 
excluded. 
 
6. Patients with previous history of transient ischemic attack or 
reversible ischemic neurological deficit were excluded. 
 
Study method: 
 
 
A total of 50 patients who presented with acute ischemic stroke 
were enrolled into the study. That the stroke was an ischemic one was 
confirmed by CT scan. As soon as the patients were admitted within 48 
hours of onset of stroke, serum samples were taken for hs-CRP 
estimation. Serum hs-CRP levels were also estimated in fifty normal 
patients (without any evidence of acute infection, neoplasm, rheumatic 
heart disease, collagen vascular disease, hypertension, DM, IHD) and 
was found to be within normal limits. 
 
Standard guidelines for the treatment of acute ischemic stroke were 
followed. None of the patients received any thrombolytic treatment. 
They were treated only with antiedema measures and antiplatelets such 
as aspirin alone and with good nursing care and physiotherapy.
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The patients were reviewed after 4 weeks after onset of stroke and 
 
were stratified using the Glasgow Outcome Scale (GOS). The serum hs-
CRP level was correlated with the functional recovery of patients after 4 
weeks using the GOS. Patients with score of 4 and 5 were included in the 
good outcome and patients with score of 1, 2, 3 were included in the 
poor outcome cateogory. 
 
Definitions followed in the Study: 
 
1. Stroke 
 
 
Stroke (as defined by WHO) was defined as rapidly developing 
clinical signs of focal or global (for patients in coma) neurological deficit 
lasting more than 48 hours or leading to death with no apparent cause 
other than vascular origin. 
 
2. hs-CRP: 
 
 
Cut off value for hs-CRP for assessing the prognosis of stroke in 
this study was taken as ≥ 10.1 mg/L and the serum hs-CRP level was 
correlated with the functional recovery of patients after 4 weeks using 
the GOS. This was based on a study by Muir KW et al who found that 
hs-CRP levels above 10.1mg/L when measured within 72 hours of stroke 
predicted mortality over 4 years102. 
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3. GOS: 
 
 
The GOS was utilized to assess the functional outcome and 
residual neurological deficit. The GOS has frequently been used in trials 
involving stroke and brain injuries. It is a well validated scale with good 
interobserver agreement. 
 
GLASGOW OUTCOME SCALE (GOS): 
 
 
1 - indicates death 
 
 
2 - a vegetative state (the patient is unable to interact with the 
environment) 
 
3 - severe disability (the patient is unable to live independently but can    
follow commands) 
 
4 - moderate disability (the patient is capable of living independently but 
unable to return to work or school) 
 
5 - mild or no disability (the patient is able to to return to work or 
school) 
 
 
Favourable outcome was defined as a score of 4 or 5 and 
unfavourable outcome as a score of 1, 2 , or 3.
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4. Hypertension: 
 
 
Hypertension in this study was taken as BP ≥ 140/90 mmHg as per 
 
JNC VIII 
 
 
MEASUREMENT OF hs-CRP 
 
 
The Quantia CRP-US (from Tulip Diagnostics Pvt. Ltd) was used 
for the measurement of hs-CRP. Quantia CRP is a turbidimetric 
immunoassay for ultrasensitive determination of CRP in human serum 
and is based on the principle of agglutination reaction . The test 
specimen is mixed with quantia CRP US latex reagent and activation 
buffer and allowed to react. Presence of CRP in the test specimen results 
in the formation of an insoluble complex producing a turbidity, which is 
measured at wavelength between 505-578 nm. The increase in turbidity 
corresponds to the concentration of CRP in the test specimen. 
 
Test procedure: 
 
        400 microlitre of quantia CRP US activation buffer (R1) was 
pipetted out and added to 100 microlitre of Quantia CRP US latex 
reagent (R2) in the measuring cuvette. It was mixed well and incubated 
for 5 minutes. 5 microlitre of test specimen was added and mixed gently. 
Absorbance (A1) was read exactly at 10 seconds and absorbance (A2) 
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was read again at the end  of exactly 4 minutes. ∆A (A2-
A1) for test specimen was calculated. 
 
∆A gives the CRP concentration (‘C’) of the test specimen. 
 
 
The CRP concentration C was multiplied with the dilution factor 
(F) of the test specimen for obtaining the concentration of CRP in the test 
specimen. 
 
 
 
Concentration of CRP in the test specimen in mg/dl=C x F, 
 
 
( where F is the dilution factor of the test specimen) 
 
 
The quantia CRP US reagent has been designed to measure CRP 
concentrations in the range of 0.015-1.0 mg/dl and is linear within the 
measuring range. 
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STATISTICAL ANALYSIS: 
 
 
The collected data was analysed with SPSS 16.0 version.To describe 
about the data descriptive statistics frequency analysis, percentage 
analysis were used for categorical variables and the mean & S.D 
were used for continuous variables. To find the significant difference 
between the bivariate samples in Independent groups (Male & 
Female) Unpaired sample t-test was used. To find the significance in 
categorical data Chi-Square test was used. In both the above 
statistical tools the probability value .05 is considered as significant 
level.  
       
 
P - Value Highly Significant at P ≤ .01 
 
 
 
     
 
P - Value  Significant at P ≤ .05 
 
 
 
     
 
P -Value No Significant at P ≥ .05 
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  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Female 26 52.0 52.0 52.0 
Male 24 48.0 48.0 100.0 
Total 50 100.0 100.0   
       
Descriptive studies 
 No  Maximum Minimum Mean Std.deviation 
Age valid 
N(listwise 
50 
50 
45 70 59.90 7.360 
 
 
 No  Maximum Minimum Mean Std.deviation 
Age valid 
N(listwise 
26 
26 
47 70 60.65 6.852 
 
 
 
 
 
 
 No 
 
Maximum Minimum Mean Std.deviation 
 
Age valid 
N(list wise) 
 
 
24 
 
24 
45 70 59.08 7.940 
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 50 
SEX * SSCORE 
       
 
 
  
SSCORE 
Total 
 
Favourable Unfavourable 
 SEX F Count 12 14 26 
 % within 
SSCORE 
66.7% 43.8% 52.0% 
 M Count 6 18 24 
 % within 
SSCORE 
33.3% 56.3% 48.0% 
 Total Count 18 32 50 
 % within 
SSCORE 
100.0% 100.0% 100.0% 
 
       
 
Chi-Square Tests 
 
  Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. (1-
sided) 
 Pearson 
Chi-Square 
2.424a 1 .119     
 Continuity 
Correctionb 
1.593 1 .207     
 Likelihood 
Ratio 
2.460 1 .117     
 Fisher's 
Exact Test 
      .149 .103 
 N of Valid 
Cases 
50         
  
 \ 
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Favourable Unfavourable 
 Female 12 14 
 Male 6 18 
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SEX * Hs-CRP LEVEL range 
      Crosstab 
  
Hs-CRP LEVEL range 
Total HIGH NORMAL 
 
 
 
 
 
 
 
 
 
SEX 
 
 
 
 
 
 
 
F 
 
 
 
 
 
 
Count 
15 11 26 
% within 
Hs-CRP 
LEVEL 
range 
44.1% 68.8% 52.0% 
M Count 19 5 24 
% within 
Hs-CRP 
LEVEL 
range 
55.9% 31.3% 48.0% 
 
 
Total 
 
 
Count 
34 16 50 
% within 
Hs-CRP 
LEVEL 
range 
100.0% 100.0% 100.0% 
      
Chi-Square Tests 
  Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) Exact Sig. (1-sided) 
Pearson 
Chi-Square 2.645a 1 .104     
 53 
Continuity 
Correctionb 1.750 1 .186     
Likelihood 
Ratio 2.698 1 .100     
Fisher's 
Exact Test       .135 .092 
N of Valid 
Cases 50         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
  
HIGH NORMAL 
  
 
Female 15 11 
  
 
Male 19 5 
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Hs-CRP LEVEL range 
 
 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
 
Valid NORMAL 16 32.0 32.0 32.0 
 
 
HIGH 34 68.0 68.0 100.0 
 
 
Total 50 100.0 100.0   
 
        
 
 
 
 
 
 
Time of sample collection 
 
 No Mean in hrs SD Std.error of 
mean 
Time of 
sample 
collection 
50 13.96 9.95 1.048 
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 Hs-CRP LEVEL range * SSCORE 
   
        
 
Crosstab 
 
 
  
SSCORE 
Total 
 
 
Favourable Unfavourable 
 
 
Hs-CRP 
LEVEL 
range 
NORMAL Count 15 1 16 
 
 
% within 
SSCORE 
83.3% 3.1% 32.0% 
 
 
HIGH Count 3 31 34 
 
 
% within 
SSCORE 
16.7% 96.9% 68.0% 
 
 
Total Count 18 32 50 
 
 
% within 
SSCORE 
100.0% 100.0% 100.0% 
 
 
 
Chi-Square Tests 
 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact 
Sig. (1-
sided) 
 
 
Pearson 
Chi-Square 
34.059a 1 .000     
 
 
Continuity 
Correctionb 
30.473 1 .000     
 
 
Likelihood 
Ratio 
37.567 1 .000     
 
 
Fisher's 
Exact Test 
      .000 .000 
 
 
Linear-by-
Linear 
Association 
33.378 1 .000     
 
 
N of Valid 
Cases 
50         
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  Favourable Unfavourable 
Normal 15 1 
High 3 31 
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Group Statistics 
 
Hs-CRP LEVEL 
range N 
Mea
n 
Std. 
Deviat
ion Std. Error Mean 
 AGE NORMAL 16 57.9 6.971 1.743 
 HIGH 34 60.8 7.457 1.279 
 
          
 
  
Levene's 
Test for 
Equality of 
Variances t-test for Equality of Means 
 
F Sig. t df Sig. (2-tailed) 
Mean 
Differenc
e 
Std. 
Error 
Differen
ce 
95% Confidence 
Interval of the 
Difference 
 
Lower Upper 
 AGE Equal 
variances 
assumed 
.17
2 
.680 -1.303 48 .199 -2.886 2.216 -7.341 1.569 
  
 
 
 
Equal 
variances 
not 
assumed 
     
 
 
-1.335 
 
 
 
31.369 
 
 
 
.191 
 
 
 
 
-2.886 
 
 
 
2.162 
 
 
 
-7.293 
 
 
 
1.521 
  
 
           
 
 
Group Statistics 
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SSCORE N Mean 
Std. 
Deviati
on 
Std. 
Error 
Mean 
 Hs-
CRP 
LEVEL 
Favourable 18 9.7 1.5761 .3715 
 Unfavourab
le 
32 12.3 1.8531 .3276 
 
             
 
Independent Samples Test 
 
  
Levene's 
Test for 
Equality of 
Variances t-test for Equality of Means 
 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Differe
nce 
Std. Error 
Differenc
e 
95% Confidence 
Interval of the 
Difference 
 Lower Upper 
 Hs-CRP 
LEVEL 
Equal 
variances 
assumed 
.64
3 
.427 -5.123 48 .000 -
2.656
6 
.5185 -
3.6992 
-
1.6140 
 Equal 
variances not 
assumed 
    -5.364 40.340 .000 -2.6566 .4953 -
3.6574 
-
1.6558 
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SMOKER 
 
 
  
Frequenc
y 
Perce
nt 
Valid 
Perce
nt 
Cumulati
ve 
Percent 
 
 
Valid NO 29 58.0 58.0 58.0 
 
 
YES 21 42.0 42.0 100.0 
 
 
Total 50 100.0 100.0   
 
        
 
ALCOHOLIC 
 
 
  
Frequenc
y 
Perce
nt 
Valid 
Perce
nt 
Cumulati
ve 
Percent 
 
 
Valid NO 31 62.0 62.0 62.0 
 
 
YES 19 38.0 38.0 100.0 
 
 
Total 50 100.0 100.0   
 
        
 
 HYPERTENSION 
 
 
  
Frequenc
y 
Perce
nt 
Valid 
Perce
nt 
Cumulati
ve 
Percent 
 
 
Valid NO 20 40.0 40.0 40.0 
 
 
YES 30 60.0 60.0 100.0 
 
 
Total 50 100.0 100.0   
 
         
  Smokers Alcholic HPT 
No 29 31 20 
Yes 
21 19 30 
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SMOKER * Hs-CRP LEVEL range 
   
        
 
Crosstab 
 
   
Hs-CRP LEVEL 
range 
Total  
 
HIGH NORMAL 
 
 
SMOKER NO Count 17 12 29 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
50.0% 75.0% 58.0% 
 
 
YES Count 17 4 21 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
50.0% 25.0% 42.0% 
 
 
Total Count 34 16 50 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
100.0% 100.0% 100.0% 
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Chi-Square Tests 
 
 
  Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact 
Sig. (1-
sided) 
 
 
Pearson 
Chi-Square 
2.791a 1 .095     
 
 
Continuity 
Correctionb 
1.860 1 .173     
 
 
Likelihood 
Ratio 
2.900 1 .089     
 
 
Fisher's 
Exact Test 
      .129 .085 
 
 
N of Valid 
Cases 
50         
 
 
  HIGH NORMAL 
   
 
No 17 12 
   
 
Yes 17 4 
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SMOKER * SSCORE 
      Crosstab 
  
SSCORE 
Total Favourable Unfavourable 
SMOKER NO Count 13 16 29 
% within 
SSCORE 
72.2% 50.0% 58.0% 
YES Count 5 16 21 
% within 
SSCORE 
27.8% 50.0% 42.0% 
Total Count 18 32 50 
% within 
SSCORE 
100.0% 100.0% 100.0% 
      Chi-Square Tests 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson 
Chi-Square 
2.335a 1 .126     
Continuity 
Correctionb 
1.512 1 .219     
Likelihood 
Ratio 
2.397 1 .122     
Fisher's 
Exact Test 
      .149 .109 
N of Valid 
Cases 
50         
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  Favourable Unfavourable 
   
 
Female 13 16 
   
 
Male 5 16 
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 ALCOHOLIC * Hs-CRP LEVEL range 
  
        
 
Crosstab 
 
 
 
  
Hs-CRP LEVEL 
range 
Total  
 
HIGH NORMAL 
 
 
ALCOHOLIC NO Count 19 12 31 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
55.9% 75.0% 62.0% 
 
 
YES Count 15 4 19 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
44.1% 25.0% 38.0% 
 
 
Total Count 34 16 50 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
100.0% 100.0% 100.0% 
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  HIGH NORMAL 
   
 
No 19 12 
   
 
Yes 15 4 
   
       
  
 
     
       
 
 
 
 
 
 
 
    
 
 
 
 
Chi-Square Tests 
 
  Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact 
Sig. (1-
sided) 
 
 
Pearson Chi-
Square 
1.688a 1 .194     
 
 
Continuity 
Correctionb 
.974 1 .324     
 
 
Likelihood 
Ratio 
1.749 1 .186     
 
 
Fisher's Exact 
Test 
      .228 .162 
 
 
N of Valid 
Cases 
50         
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        Crosstab 
   SSCORE Total 
 
 
Favourable Unfavourable  
 
 
ALCOHOLIC NO Count 14 17 31 
 
 
% within 
SSCORE 
77.8% 53.1% 62.0% 
 
 
YES Count 4 15 19 
 
 
% within 
SSCORE 
22.2% 46.9% 38.0% 
 
 
Total Count 18 32 50 
 
 
% within 
SSCORE 
100.0% 100.0% 100.0% 
 
        
 
Chi-Square Tests 
 
 
  Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact 
Sig. (1-
sided) 
 
 
Pearson Chi-
Square 
2.972a 1 .085     
 
 
Continuity 
Correctionb 
2.017 1 .155     
 
 
Likelihood 
Ratio 
3.101 1 .078     
 
 
Fisher's Exact 
Test 
      .130 .076 
 
 
N of Valid 
Cases 
50         
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 Favourable unfavaurable 
Yes  4 15 
no 14 17 
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 HYPERTENSION * Hs-CRP LEVEL range 
        
 
Crosstab 
 
   
Hs-CRP LEVEL 
range 
Total  
 
HIGH NORMAL 
 
 
 
HYPERTENSION 
NO Count 10 10 20 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
29.4% 62.5% 40.0% 
 
 
YES Count 24 6 30 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
70.6% 37.5% 60.0% 
 
 
Total Count 34 16 50 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
100.0% 100.0% 100.0% 
 
        
 
 
 
 
 
Chi-Square Tests 
 
 
  Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact 
Sig. (1-
sided) 
 
 
Pearson Chi-
Square 
4.963a 1 .026     
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Continuity 
Correctionb 
3.680 1 .055     
 
 
Likelihood Ratio 4.937 1 .026     
 
 
Fisher's Exact 
Test 
      .034 .028 
 
 
N of Valid Cases 50         
 
  
  
       
  HIGH NORMAL 
   No 10 10 
   Yes 24 6 
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HYPERTENSION * SSCORE 
        
 
Crosstab 
 
 
  
SSCORE 
Total 
 
 
Favourable Unfavourable 
 
 
 
HYPERTENSION 
NO Count 10 10 20 
 
 
% within 
SSCORE 
55.6% 31.3% 40.0% 
 
 
YES Count 8 22 30 
 
 
% within 
SSCORE 
44.4% 68.8% 60.0% 
 
 
Total Count 18 32 50 
 
 
% within 
SSCORE 
100.0% 100.0% 100.0% 
 
        
 
Chi-Square Tests 
 
 
  Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact 
Sig. (1-
sided) 
 
 
Pearson Chi-
Square 
2.836a 1 .092     
 
 
Continuity 
Correctionb 
1.913 1 .167     
 
 
Likelihood Ratio 2.821 1 .093     
 
 
Fisher's Exact 
Test 
      .134 .084 
 
 
N of Valid Cases 50         
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  Favourable Unfavourable 
   
 
No 10 10 
   
 
Yes 8 22 
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SERUM CHOLESTEROL * Hs-CRP LEVEL range 
        
 
Crosstab 
 
   
Hs-CRP LEVEL 
range 
Total  
 
HIGH NORMAL 
 
 
 SERUM 
CHOLESTEROL 
HIGH Count 14 1 15 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
41.2% 6.3% 30.0% 
 
 
NORMAL Count 20 15 35 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
58.8% 93.8% 70.0% 
 
 
Total Count 34 16 50 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
100.0% 100.0% 100.0% 
 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact 
Sig. (1-
sided) 
 
 
Pearson Chi-
Square 
6.320a 1 .012     
 
 
Continuity 
Correctionb 
4.766 1 .029     
 
 
Likelihood Ratio 7.535 1 .006     
 
 
Fisher's Exact 
Test 
      .019 .011 
 
 
N of Valid Cases 50         
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HIGH NORMAL 
   High 14 1 
   Normal 20 15 
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SERUM CHOLESTEROL * SSCORE 
        
 
Crosstab
 
 
  
SSCORE 
Total 
 
 
Favourable 
Unfavourabl
e 
 
 
 SERUM 
CHOLESTEROL 
HIGH Count 2 13 15 
 
 
% within 
SSCORE 
11.1% 40.6% 30.0% 
 
 
NORMAL Count 16 19 35 
 
 
% within 
SSCORE 
88.9% 59.4% 70.0% 
 
 
Total Count 18 32 50 
 
 
% within 
SSCORE 
100.0% 100.0% 100.0% 
 
        
 
 
 
 
Chi-Square Tests 
 
 
  Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact 
Sig. (1-
sided) 
 
 
Pearson Chi-
Square 
4.778a 1 .029     
 
 
Continuity 
Correctionb 
3.476 1 .062     
 
 
Likelihood Ratio 5.299 1 .021     
 
 
Fisher's Exact 
Test 
      .052 .028 
 
 
N of Valid Cases 50         
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  Favourable Unfavourable 
   
 
High 2 13 
   
 
Normal 16 19 
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CARDIAC DISEASE * SSCORE 
        
 
Crosstab 
 
 
  
SSCORE 
Total 
 
 
Favourable Unfavourable 
 
 
 
CARDIAC 
DISEASE 
NO Count 16 24 40 
 
 
% within 
SSCORE 
88.9% 75.0% 80.0% 
 
 
YES Count 2 8 10 
 
 
% within 
SSCORE 
11.1% 25.0% 20.0% 
 
 
Total Count 18 32 50 
 
 
% within 
SSCORE 
100.0% 100.0% 100.0% 
 
        
 
 
 
 
 
 
Chi-Square Tests 
 
 
  Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact 
Sig. (1-
sided) 
 
 
Pearson 
Chi-Square 
1.389a 1 .239     
 
 
Continuity 
Correctionb 
.656 1 .418     
 
 
Likelihood 
Ratio 
1.493 1 .222     
 
 
Fisher's 
Exact Test 
      .295 .212 
 
 
N of Valid  50         
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 favourable unfavourable 
no 16 24 
yes 2 8 
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Cardiac disease 
 
 
        
 
Crosstab 
 
   
Hs-CRP LEVEL 
range 
Total  
 
HIGH NORMAL 
 
 
 
CARDIAC 
DISEASE 
NO Count 26 14 40 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
76.5% 87.5% 80.0% 
 
 
YES Count 8 2 10 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
23.5% 12.5% 20.0% 
 
 
Total Count 34 16 50 
 
 
% 
within 
Hs-
CRP 
LEVEL 
range 
100.0% 100.0% 100.0% 
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Chi-Square Tests 
 
  Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact 
Sig. (1-
sided) 
 
 
Pearson 
Chi-Square 
.827a 1 .363     
 
 
Continuity 
Correctionb 
.281 1 .596     
 
 
Likelihood 
Ratio 
.883 1 .347     
 
 
Fisher's 
Exact Test 
      .468 .307 
 
 
N of Valid 
Cases 
50         
 
  
   
 
  HIGH NORMAL 
  
 
No 26 14 
  
 
Yes 8 2 
  
       
 
 
     
      
      
      
      
      
      
       
 
 80 
 
 
      
       
       
       
 
 
 
 
 
 
 
 
 
SSCORE 
 
 
  Frequency Percent 
Valid 
Percen
t 
Cumulative 
Percent 
 
 
Valid Favourable 18 36.0 36.0 36.0 
 
 
Unfavourabl
e 
32 64.0 64.0 100.0 
 
 
Total 50 100.0 100.0   
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Table 12: hs-CRP Vs GOS Score 
 
 
GOS hs-CRP (mg/L) Total 
    
 < 10.1 >10.1  
    
1 0(0%) 2(4%) 2(4%) 
    
2 0(0%) 13(26%) 13(26%) 
    
3 0(0%) 17(34%) 17(34%) 
    
4 7(14%) 3(6%) 10(20%) 
    
5 8(16%) 0(0%) 8(16%) 
    
Total 15(30%) 35(70%) 50(100%) 
    
 
 
hs-CRP Vs GOS Group: 
 
 
Out of the 34% cases with GOS score of 4 or 5, i.e those with 
favourable outcome, 30% had CRP < 10.1 mg/L and 4% had CRP > 10.1 
mg/L. 
 
All the remaining 66% cases with GOS score of 1, 2 or 3, (i.e 
unfavourable outcome) had hs-CRP > 10.1 mg/L. 
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Table 13: hs-CRP Vs GOS Group 
 
  GOS group hs-CRP (mg/L) Total 
      
   < 10.1 > 10.1  
      
  Favourable 15(30%) 2(4%) 17(34%) 
      
  Unfavourable 0(0%) 33(66%) 33(66%) 
      
  Total 15(30%) 35(70%) 50(100%) 
      
P= 0.000 SIGNIFICANT   
 
 
SENSITIVITY/ SPECIFICITY TEST FOR hs-CRP: 
 
Table 14: Sensitivity/ Specificity Test for hs-CRP 
 
Parameter Estimate Lower - Upper 95%  
  CIs  
    
Sensitivity 100% (89.57, 100)  
    
Specificity 88.24% (65.66, 96.71)  
    
Positive Predictive 
94.29% (81.39, 98.42) 
 
Value 
 
   
    
Negative Predictive 
100% (79.61, 100) 
 
Value 
 
   
    
Diagnostic Accuracy 96% (86.54, 98.9)  
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Thus hs-CRP is 100% sensitive and 88.24% specific as a 
prognostic tool in acute ischemic stroke. hs-CRP has a diagnostic 
accuracy of 96% in patients with acute ischemic stroke. 
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DISCUSSION
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DISCUSSION 
 
 
 
The correlation between hs-CRP levels measured within 48 hours 
of onset of stroke to that of the functional outcome of the patient at the 
end of 4 weeks (using GOS) was carried out. 
 
Out of the 50 cases enrolled in the study, 35 cases (70%) had CRP 
values > 10.1 mg/L and 15 cases (30%) had CRP < 10.1 mg/L. 
 
Out of the 35 cases with CRP > 10.1 mg/L, 4% had GOS score of 
1, 26% cases had GOS score of 2, 34% cases had GOS score of 3. 
 
On the other hand, of the remaining 15 cases with CRP < 10.1 
mg/L, none had a GOS score of 1, 2 or 3. 14% cases had a GOS score of 
4 and 16% cases had a GOS score of 5. 
 
Out of the 50 patients, 2 died. Both of them had very high hs-CRP 
levels. Thus patients with CRP levels < 10.1 mg/L had a relatively 
favourable outcome (GOS score of 1, 2 or 3) when compared to patients 
with levels > 10.1 mg/L (GOS score of 4 and 5). 
 
      In our study following statistical analysis were done 
 
1. Mean age of the patients included in this study was 59.90 with SD 
of 7.360 
2. Mean age of female patients was 60.65 with SD 6.852 
 
 
3. Mean age for male patients was 59.08 with std .deviation of 7.940  
 
4. Out of  26 females enrolled in this study 15 had high Hs-crp level 
and remaining 9 had normal Hs –crp level. 
 
5. Out of 24 males enrolled in this study 19 had high levels and 
remaining 5 had normal levels. 
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6. Mean time of samle collection is 13.96 with SD of 9.95 hrs 
 
7. In this study out of 34 patients who had value 31  people fell in 
unfavourable group  
P value – highly significant  =0.000 
 
8. Out of 29 non smokers 17 had  high value and 12 had normal 
value and out of 21 smokers 17 had high value and 4 had normal 
value 
P value- 0.095  non significant 
 
9. Out of  29 smokers 13 had favourable GOS score  remaining 16 
had unfavourable score and out of 21 smokers 5 had favourable 
score and remaining 16 had unfavourable score 
P value – 0.126  not significant 
 
10. Out of 31 nonalcoholics in this study 19 had high levels of Hs-crp 
remaining 12 had normal levels and out of 19 alcoholics 15 had 
high high values remaining 4  had normal value 
P value- 0.194 not significant 
 
11. Out of 31 non alcoholics 14 had favourable GOS score remaining 
17 had unfavourable score and out of 19 alcoholics 4 had 
favourable GOS score and remaining 15 had unfavourable score  
Pvalue – 0.089   non significant 
 
12. Out of 30 persons with high BP 24 had high Hs-crp levels and 6 
had normal levels .out of 20 with normal BP 10 had high levels 
and the remaining 10 had normal levels 
P value   -  0.026   significant 
 
13. Out of 30 hypertensives 8 had favourable GOS score and 22 had 
unfavourable score .out of 20 non hypertensives 10 had favourable 
score and remaining 10 had unfavourable score  
P value-  0.092   not significant 
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14. Out of  15 patients with 14 had high levels of Hs-crp remaining 
one patient had normal level.out of 35 patients with normal serum 
cholesterol levels 20 had high Hs-crp values remaining 15 had 
normal values 
P value-  0.012  high significant 
 
15. Out of 35 patients who had normal serum cholesterol level 16 
patients had favourable score and remaining 19 had unfavourable 
score. Out of 15 patients who had high serum cholesterol level 2 
had favourable score and 13 had unfavourable score 
P value- 0.029  significant 
 
16. Out of 40 patients who had normal cardiac status 26 had high Hs-
crp levels and 14 had normal level. Out of 10 cardiac patients 8 
had high levels and 2 had normal levels 
P value  -0.363   not significant 
 
17.  Out of 40 non- cardiac patients   16 had favourable GOS score 
and 24 unfavourable score. Out of 10 cardiac patients 2 had 
favourable score and 8 had unfavourable score 
P value-  0.239  not significant 
T
his is consistent with the various studies conducted using hs-CRP 
as a prognostic indicator of acute ischemic stroke. 
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Table 15: Studies conducted using hs-CRP as a prognostic 
indicator 
 
 
S. No Study Year 
   
1. Di Napoli 2001, 2002, 2005 
   
2. Yusuf Tamam et al 2005 
   
3. Muir KW, Weir CJ, Alwar W et al 1999 
   
4. Mitchell S V Elkind et al 2006 
   
5. Ufuk Emre et al 2007 
   
6. Winbeck K et al 2002 
   
7. Kocer A et al 2005 
   
8. Rost N S et al 2001 
   
9. Cao J J et al 2003 
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The correlation of hs-CRP levels with age and gender was studied. There 
was no statistically significant correlation between age and gender of the 
patient with the hs-CRP levels. This may be because of the small sample 
size of our study group. But in a study conducted by So Yeon Ryu et al 
in 2005, age had an independent association with plasma hs-CRP 
whereas gender showed no significant association with plasma hs-CRP. 
Also another study conducted by Rohde Lep et al in 1999 concluded that 
hs-CRP levels were statistically significant with age, number of 
cigarettes smoked per day, BP, total cholesterol. 
 
In our study, smoking and alcohol had no statistical significance 
with hs-CRP levels. This is in contrast to a study conducted by So Yeon 
Ryu et al in 2005, where smoking had a significant correlation with 
plasma hs-CRP levels. Smoking is well supposed to give chemical and 
oxidative stimuli to the cardiovascular system and cause inflammation. 
The same study also reported that moderate alcohol consumption reduces 
circulating hs-CRP. Moderate alcohol consumption has anti-
inflammatory effects. The mechanism causing moderate alcohol to 
decrease CRP levels needs further investigation. It involves nuclear 
factor (NF) – κB (Blanco – Colio et al 2000). NF-κB is a redox sensitive 
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transcription factor which activates geans involved in the immune, 
inflammatory or acute phase response, such as cytokines IL – 6 and TNF 
- α which regulates CRP production by liver. Another study conducted 
by M. Averina et al in 2003  
 
In our study, total serum cholesterol did not have statistically 
significant correlation with hs-CRP levels. This is in contrast to a study 
conducted by So Yeon Ryu et al in 2005. A limitation of our study was 
that only total serum cholesterol was estimated and not the complete 
lipid profile. 
 
Our study showed a statistically significant correlation between 
high BP and hs-CRP. This is consistent with the study conducted by So 
Yeon Ryu et al in 2005 and Blackburn R et al in 2001. 
 
Diabetes had no statistical significance with hs-CRP in our study. 
This is in contrast to many of the previous studies. This may be because 
of the small sample size and also because of the fact that our study 
included only acute ischemic stroke patients; it was not done exclusively 
on diabetic subjects. 
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Table 16: Studies showing significant correlation between 
 
hs-CRP levels and DM 
 
 
S.No Study Year 
   
1. Blackburn R. et al 2001 
   
2. Minna Soinio et al 2006 
   
3. So Yeon Ryu et al 2005 
   
 
 
Our study also did not show a statistically significant correlation 
between IHD and hs-CRP levels. This is in contrast to many of the 
previous studies. This may be because our study included only ischemic 
stroke patients, it did not include IHD cases without stroke. 
 
Table 17: Studies showing significant correlation 
 
between hs-CRP levels and IHD 
 
 
S.No Study Year 
   
1 Liuzzo et al 1994 
   
2 Ferreiros et al 1999 
   
3 winter et al 1999 
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the major difference between our study and those of other studies 
mentioned above was that our study involved only hs-CRP levels and not 
other acute phase reactants like fibrinogens. Also, in our study we assessed 
the outcome of patients with acute ischemic stroke at the end of four weeks 
and not at the end of one year. Also, we measured the CRP levels only 
within 48 after the onset of ischemic stroke and not at the end of four 
weeks or at the time of discharge. This was because of the cost involved in 
the measurement of hs-CRP. The other reason, why our study did not have 
significant correlation with age, sex, DM, IHD was that our study sample 
size was very small. 
 
The prognostic importance of the 48-hour concentration of CRP may be 
partly related to the extent of ischemic necrosis and partly to the unknown 
individual determinants of the intensity of the acute phase reactants. CRP is a 
very vital indicator of the inflammatory states during the acute phase of an 
ischemic stroke. 
 
Knowledge of the prognostic influence of the levels of CRP in the outcome 
of stroke of atherothrombotic etiology helps the clinician to offer realistic 
expectations to the families of stroke victims. 
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Thus, CRP can be routinely measured for all stroke patients , as it has  been 
found to provide a statistically significant level of prognostic information 
as to the eventual outcome of stroke both in short term such as in our study 
and also over a longterm as was shown in the study by DiNapoli  
 
 
Also, CRP has a direct relationship with other cardiovascular risk factors, 
like smoking, alcohol consumption, hypertension, diabetes and cholesterol. Thus 
CRP levels may be a marker for preclinical cardiovascular disease. 
 
As CRP was found to be an independent risk indicator of further 
cardiovascular and neurovascular events as shown by the subset of Framingham 
study, routine CRP screening of susceptible population like chronic smokers and 
sibilings and first degree relatives of patients with IHD and stroke may prove a 
valuable indicator for predicting future athreothrombotic events and then it can 
be assessed as a routine indicator for aspirin prophylaxis.  
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CONCLUSION
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CONCLUSION 
 
 
 
 
• hs-CRP levels showed statistically significant elevation in patients 
with high blood pressure. 
 
• hs-CRP levels had no significant correlation with age or gender. 
 
 
• hs-CRP did not show a statistically significant correlation with 
smoking or cholesterol intake. 
 
• There was no statistically significant correlation between hs-CRP 
levels and those with diabetes or IHD. 
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ANNEXURES 
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PROFORMA 
 
Name: IP No: Serial No: 
 
Age: 
 
Sex: 
 
Occupation: 
 
Address: 
 
 
 
 
Smoking: 
 
Alcohol: 
 
DM: 
 
HT: 
 
IHD: 
 
 
 
 
CLINICAL EXAMINATION: 
 
 
 
 
Pulse rate: BP: 
 
CVS: 
 
RS: 
 
Abdomen: 
 
CNS: 
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INVESTIGATIONS: 
 
 
 
 
Hb%: Total count: 
 
Differential count P- , L- , E- , M- , B-ESR: 
 
 
 
hs-CRP: 
 
 
 
 
Blood urea: 
 
Blood sugar: 
 
Serum creatinine: 
 
Serum electrolytes: 
 
Serum cholesterol: 
 
 
 
 
ECG: 
 
CXR-PA view: 
 
 
CT brain: 
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MASTER CHART
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NAME AGE SEX 
TIME OF 
SAMPLE 
COLLECTION 
(hrs) 
GOS 
SCORE 
Hs-CRP 
LEVEL 
Hs-CRP 
LEVEL SMOKER ALCOHOLIC 
 
HYPERTENSION 
 SERUM 
CHOLESTEROL 
 
CARDIAC 
DISEASE 
1 MR. GNANAPRAKASH 45 M 6 2 14.5 HIGH YES YES YES HIGH YES 
2 MR.GUNASEELAN 61 M 14 3 13.8 HIGH YES YES YES NORMAL NO 
3 MRS.GANDIMATHI 66 F 18 2 10.2 HIGH NO NO NO NORMAL NO 
4 MR. DAVID 46 M 21 3 11.6 HIGH YES YES YES NORMAL YES 
5 MRS.INDRAVATHI 62 F 7 3 10.6 HIGH NO S.NO NO HIGH NO 
6 MRS.MUNNIYAMMAL 67 F 15 2 10.3 HIGH NO NO NO NORMAL NO 
7 MR.ELUMALAI 53 M 13 5 8.9 NORMAL NO NO NO NORMAL NO 
8 MR.IDAYATHULLAH 63 M 19 5 9 NORMAL YES YES NO NORMAL YES 
9 MR.RADHAKRISHNAN 68 M 16 2 12.2 HIGH YES YES YES HIGH YES 
10 MRS.JAYANTHI 47 F 8 5 9.2 NORMAL NO NO YES NORMAL NO 
11 MR.JOHNSON 64 M 20 3 13.1 HIGH YES YES YES NORMAL NO 
12 MRS.DEVI 54 F 21 5 9 NORMAL NO NO NO NORMAL NO 
13 MR.RAMBAHADUR 69 M 8 1 17.2 HIGH YES YES YES HIGH YES 
14 MRS.RADHA 48 F 16 3 12.2 HIGH NO NO NO NORMAL NO 
15 MR.BALASUBRAMANIAN 65 M 17 2 11.2 HIGH YES YES YES NORMAL NO 
16 MRS.THASIRBANU 70 F 10 5 7.3 NORMAL NO NO YES NORMAL NO 
17 MR.CHANDRASEKARAN 50 M 7 3 11.3 HIGH YES YES YES HIGH NO 
18 MRS.GOMATHI 56 F 11 3 13.2 HIGH NO NO NO NORMAL NO 
19 MRS.JANAKIAMMAL 61 F 13 4 9.7 NORMAL NO NO NO NORMAL NO 
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20 MR.REMIGEORGETHOMAS 66 M 18 3 12.3 HIGH YES YES YES NORMAL NO 
21 MRS.MANJULA 57 F 11 4 9.2 NORMAL NO NO NO NORMAL NO 
22 MRS.DEVAKI 62 F 12 2 10 NORMAL NO NO YES NORMAL NO 
23 MRS.LAKSHMI 67 F 19 5 7 NORMAL NO NO YES NORMAL NO 
24 MR.SHAHUL HAMEED 52 M 9 3 14.2 HIGH YES YES YES HIGH YES 
25 MRS.GNANASOUNDARI 63 F 20 3 11.1 HIGH NO NO YES NORMAL NO 
26 MRS.SULOCHANA 68 F 8 4 10 NORMAL NO NO NO NORMAL NO 
27 MR.SELVAKUMAR 58 M 21 2 12.7 HIGH YES YES YES HIGH NO 
28 MRS.SAMPOORNAM 64 F 5 5 12 HIGH NO NO YES HIGH NO 
29 MRS.VASANTHAMANI 69 F 14 3 10.7 HIGH NO NO NO NORMAL NO 
30 MRS. MARY 59 F 15 4 10 NORMAL NO NO NO NORMAL NO 
31 MR.KUMARESAN 65 M 6 2 14.3 HIGH YES YES YES HIGH YES 
32 MR.SIVASANKARAN 51 M 7 5 10 NORMAL YES YES YES HIGH NO 
33 MR.SHANMUGAM 60 M 16 3 11.2 HIGH NO YES YES NORMAL NO 
34 MR.ARAVINDAN 70 M 12 1 16.9 HIGH YES YES YES HIGH NO 
35 MRS.RAMESWARI 56 F 6 4 10 NORMAL YES YES NO NORMAL YES 
36 MR.GOVINDARAJALU 57 M 11 2 15.1 HIGH NO YES YES NORMAL YES 
37 MRS.SUDHA 66 F 5 3 10.3 HIGH NO NO YES HIGH NO 
38 MR.VENKATESH 58 M 17 4 13 NORMAL NO NO YES NORMAL NO 
39 MR.MARIAPPAN 67 M 12 2 11.3 HIGH YES NO YES HIGH NO 
40 MRS.THARA 59 F 7 3 12.3 HIGH NO NO YES NORMAL NO 
41 MR.SELVAM 46 M 18 4 11.9 HIGH YES NO YES NORMAL NO 
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42 MRS.TAMILMANI 68 F 10 2 13.1 HIGH NO NO YES HIGH NO 
43 MRS.PRIYASENTHIL 69 F 8 4 11.1 HIGH NO NO YES NORMAL NO 
44 MR.THIRUNAVUKARASU 60 M 19 3 12.9 HIGH YES NO NO NORMAL NO 
45 MRS.SHANTHI 55 F 20 3 11.2 HIGH NO NO NO NORMAL NO 
46 MR.ELANGO 70 M 6 2 12.3 HIGH YES NO YES HIGH YES 
47 MRS.PRIYADARSHINI 47 F 21 4 9 NORMAL NO NO NO NORMAL NO 
48 MRS.SANGEETHAMAL 58 F 14 3 10.3 HIGH NO NO NO NORMAL NO 
49 MR.RAMAHATHULLAH 54 M 15 4 7.9 NORMAL YES YES NO NORMAL NO 
50 MRS.MALRVIZHI 59 F 16 2 11.1 HIGH NO NO NO NORMAL NO 
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ABBREVIATIONS 
 
 
 
 
% - Percentage 
APP - Acute phase protein 
BP - Blood pressure 
CAHD - Coronary artery heart disease 
CHD - Coronary heart disease 
CI - Confidence Interval 
CRP-US - C-Reactive Protein ultra sensitive 
DM - Diabetes mellitus 
Gp - Group 
hs-CRP - High sensitivity C-Reactive Protein 
HT - Hypertension 
IHD - Ischemic heart disease 
IL - Interleukin 
JNC - Joint National Committee 
mg/L - Milligram/litre 
MI - Myocardial infarction 
m-RNA - Messenger – RNA 
OCP - Oral contraceptive pill 
SAA - Serum amyloid A 
SAH - Subarachnoid haemorrhage 
SD - Standard deviation 
TIA - Transient ischemic attack 
yrs - Years 
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